Navigation Links
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Date:12/21/2007

HORSHAM, Pa. and KENILWORTH, N.J., Dec. 21 /PRNewswire-FirstCall/ -- Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced they have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADE(R) (infliximab), an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy, which is currently in Phase 3 trials. Effective upon regulatory approval of golimumab in the EU, the revised agreement will extend the duration of Schering-Plough's rights to exclusively market REMICADE in its current marketing territories outside the United States beyond 2014 to match the current duration of its exclusive marketing rights for golimumab product. Schering-Plough's marketing rights to both products will now extend for 15 years after the first golimumab commercial sale.

In addition, Centocor will receive a progressively increased share of profits on Schering-Plough's distribution of both products in the Schering-Plough marketing territory between 2010 and 2014, and remaining fixed thereafter for the remainder of the term.

The revised agreement will also allow Schering-Plough to independently develop and market golimumab for the Crohn's disease indication in its territories, with an option for Centocor to participate in the program.

The parties have also agreed to utilize an autoinjector device developed by Centocor affiliate Cilag GmbH International in the commercialization of golimumab in their respective territories and have further agreed to share the autoinjector development costs. The autoinjector would allow patients to self-administer golimumab subcu
'/>"/>

SOURCE Schering-Plough Corporation; Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software
10. NUCRYST and Smith & Nephew Revise Agreements
11. Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ ... 13.0. NoteSwift is the bridge between the EHR and ... document clinical information at the point of care. NoteSwift ... note by more than half – and virtually eliminates ... providers state impedes EHR use according to the June ...
(Date:10/1/2014)... 01, 2014 Scientists at the University ... that target immune system proteins has the power to ... posted details of the new study on their website. ... , Researchers in the UWA School of Pathology and ... to mice with mesothelioma with promising results. , ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... 01, 2014 October is national Breast ... early detection plans while raising money for breast cancer ... Cancer Awareness Month in the effort to find ... promote the importance of having access to clean, healthy ... be linked to certain forms of cancer. , ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the ... traveling to Chennai, India, tomorrow to speak at the ... 3. , Dr. Jivraj is founder of the Anacapa ... and one of the world’s foremost prosthodontists, meaning he ... is speaking to the Indian Society of Oral Implantologists ...
Breaking Medicine News(10 mins):Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... NEW YORK, Oct. 7 The Mount Sinai Adolescent ... to 10,000 teenagers each year, announced the launch of ... , and a Facebook page to promote the important ... Legends, benefit co-chairs Stacy and Mouli Cohen designed and ...
... (BUSM) have identified genes which may influence the onset age ... in BMC Medical Genetics , are the first to ... may help identify mechanisms and therapeutic targets capable of delaying ... common neurodegenerative disorder usually occurring late in life. It ...
... , WEDNESDAY, Oct. 7 (HealthDay News) -- Could birth control ... possibly detrimental, direction? , A review of past research finds ... of mates among members of both genders in a way ... use of the pill by women, by changing her mate ...
... ... , a very common medical condition, can turn to endovenous laser therapy for treatment ... Phoenix, Arizona (PRWEB) ... affecting approximately 15 percent of men and approximately 25 percent of women. More than ...
... 7 It,s that time of year again. The annual ... Plans, large group clients, (50 or more eligible employees), began ... For this year,s enrollment season, AvMed has partnered with the ... theme of "What,s Cooking at AvMed," Client Services staff began ...
... and smart health care reform targeting AR, LA, ... Institute for Liberty today announced the launch of Keeping Small ... any health care reform legislation passed by Congress addresses the ... , "The nation faces serious economic challenges and any credible ...
Cached Medicine News:Health News:Katie Couric and the Mount Sinai Adolescent Health Center Celebrate the Launch of Breakfast of Legends Website Donated by Stacy and Mouli Cohen 2Health News:Researchers identify genes associated with onset age of Parkinson's disease 2Health News:Birth Control Pills Might Alter Mate Selection: Study 2Health News:Birth Control Pills Might Alter Mate Selection: Study 3Health News:Endovenous Laser Therapy Used for Treatment of Varicose Veins 2Health News:AvMed Health Plans' Open Enrollment Under Way 2Health News:Institute for Liberty Announces the Launch of Keeping Small Business Healthy 2
(Date:9/30/2014)... This report analyzes the worldwide markets for Enteral ... Enteral Feeding Pumps, Nasogastric Tubes, and Others. The ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. The report ...
(Date:9/30/2014)... MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... Scientific Officer, will present at the Stem Cell Meeting ... October 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... -- STUDY OBJECTIVES The objective of BCC ... overview of the current and future characteristics of ... objective is to present a comprehensive analysis and ... tool in the treatment of various diseases. ... the protein therapeutics market, which includes peptide hormones, ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... WOONSOCKET, R.I., Jan. 6, 2011 A new CVS ... a three-year period for patients with one or more ... medications as doctors direct may save the health care ... study findings revealed robust reductions in emergency department visits ...
... DIEGO, Jan. 6, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ... is scheduled to present at the 29th Annual J.P. Morgan ... Pacific Time (7:00 p.m. Eastern Time) at the Westin St. ... and Chief Executive Officer, is scheduled to provide a corporate ...
Cached Medicine Technology:CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending 2CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending 3Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: